New York State Common Retirement Fund Increases Stake in Codex DNA, Inc. (NASDAQ:DNAY)

New York State Common Retirement Fund boosted its stake in Codex DNA, Inc. (NASDAQ:DNAYGet Rating) by 1,539.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,312 shares of the company’s stock after purchasing an additional 9,683 shares during the period. New York State Common Retirement Fund’s holdings in Codex DNA were worth $55,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. K.J. Harrison & Partners Inc bought a new stake in shares of Codex DNA in the 1st quarter worth approximately $215,000. Northern Trust Corp grew its position in shares of Codex DNA by 7.4% in the 4th quarter. Northern Trust Corp now owns 67,020 shares of the company’s stock worth $723,000 after buying an additional 4,646 shares during the last quarter. Penbrook Management LLC bought a new stake in shares of Codex DNA in the 1st quarter worth approximately $774,000. Finally, Northpond Ventures LLC bought a new stake in shares of Codex DNA in the 4th quarter worth approximately $106,317,000. 87.58% of the stock is currently owned by institutional investors.

Codex DNA Price Performance

Shares of DNAY stock opened at $2.06 on Tuesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.85 and a current ratio of 3.95. Codex DNA, Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $14.99. The firm has a market cap of $60.81 million, a P/E ratio of -1.20 and a beta of 1.96. The business’s 50 day moving average price is $2.07 and its 200-day moving average price is $4.73.

Codex DNA Profile

(Get Rating)

Codex DNA, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis.

See Also

Want to see what other hedge funds are holding DNAY? Visit to get the latest 13F filings and insider trades for Codex DNA, Inc. (NASDAQ:DNAYGet Rating).

Receive News & Ratings for Codex DNA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Codex DNA and related companies with’s FREE daily email newsletter.